Cellectar Biosciences, Inc.
CLRBDrugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Jun 2027
Market Overview
Stock performance and key metrics
1 upcoming, 1 past
How CLRB's past catalysts played out
NOV-002
Ovarian Cancer
NOV-205
Hepatitis C
Iopofosine I 131 single dose
Waldenstrom Macroglobulinemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
NOV-002 | Phase 3 | Ovarian Cancer | - | - |
NOV-205 | Phase 2 | Hepatitis C | - | - |
Iopofosine I 131 single dose | Phase 2 | Waldenstrom Macroglobulinemia | - | - |
Hepatitis C
1 drug in this indication
Ovarian Cancer
1 drug in this indication
Waldenstrom Macroglobulinemia
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Cellectar Biosciences, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Cellectar Biosciences, Inc.'s (CLRB) pipeline across Phase 3, Phase 2. Its lead program is NOV-002 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Cellectar Biosciences, Inc.'s next FDA catalyst?→
Cellectar Biosciences, Inc.'s (CLRB) next tracked catalyst is a Phase 3 expected June 30, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CLRB biotech catalysts?→
Add CLRB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Cellectar Biosciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.